GonadorelinvsHMG

Gonadorelin is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to endogenous gonadotropin-releasing hormone (GnRH) produced by hypothalamic neurons in the arcuate nucleus. It binds to GnRH receptors (GnRHR), a Gq/11-coupled GPCR on pituitary gonadotroph cells, activating phospholipase C, generating IP3 and DAG, and raising intracellular calcium to trigger the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The critical pharmacological principle of gonadorelin is that its biological effect depends entirely on the pattern of administration. Pulsatile administration (mimicking the hypothalamic GnRH pulse generator, which fires approximately every 60-90 minutes) maintains gonadotroph sensitivity and produces physiological LH/FSH release. This pulsatile pattern is essential because GnRHR undergoes rapid desensitization and internalization upon continuous stimulation. Continuous or high-frequency GnRH exposure causes receptor downregulation, depleting the gonadotroph cell surface of functional receptors, and paradoxically suppresses LH and FSH — the principle exploited by GnRH agonist depot formulations (leuprolide, goserelin) used for chemical castration in prostate cancer and endometriosis.

In the context of testosterone replacement therapy (TRT), gonadorelin is used to maintain intratesticular testosterone (ITT) and spermatogenesis, which would otherwise be suppressed by exogenous testosterone through negative feedback. Exogenous testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion, causing the testes to atrophy and sperm production to cease. By providing pulsatile GnRH stimulation, gonadorelin keeps the LH signal active, maintaining Leydig cell testosterone production and Sertoli cell-supported spermatogenesis. This has made gonadorelin an increasingly popular alternative to HCG for fertility preservation during TRT, especially since the FDA's reclassification of HCG as a biologic restricted compounding availability.

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.